Predictors of long-term use of evidence-based therapies after non-ST-segment elevation acute coronary syndrome. The S-Témoin survey

International Journal of Cardiology

Volumn 133, Issue 1, 2009, Pages 32-40

  Danchin, Nicolas ^a   Diévart, François ^b   Thébaut, Jean François ^c   Grenier, Olivier ^a   Mihci, Esvet ^d   Herrmann, Marie Annick ^e   Ferrières, Jean ^f  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b Cardiology Department   (France)

^c Centre Alfred Kastler   (France)

^d SANOFI   (France)

^e BRISTOL MYERS SQUIBB   (United States)

^f CHU RANGUEIL   (France)

Author keywords

Antiplatelet; Non ST segment elevation myocardial infarction; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; CORONARY STENT; DISEASE SEVERITY; DRUG ELUTING STENT; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; SECONDARY PREVENTION;

ACUTE CORONARY SYNDROME; ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHI-SQUARE DISTRIBUTION; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME;

EID: 61849134844     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.11.060     Document Type: Article

References (40)

1. Fox K.A., Cokkinos D.V., Deckers J., et al. The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. Eur Heart J 21 (2000) 1440-1449
2. Tunstall-Pedoe H., Kuulasmaa K., Mahonen M., et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 353 (1999) 1547-1557
3. World Health Organization. Health Statistics and health information systems (2005), WHO
4. Murray C.L.J., and Lopez A.D. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020 (1996), Harvard School of Public Health, Cambridge, USA 1022
5. Hasdai D., Behar S., Wallentin L., et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 23 (2002) 1190-1201
6. Steg P.G., Goldberg R.J., Gore J.M., et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 90 (2002) 358-363
7. Goldberg R.J., Currie K., White K., et al. Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol 93 (2004) 288-293
8. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40 (2002) 1366-1374
9. Bertrand M.E., Simoons M.L., Fox K.A., et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the management of acute coronary syndromes of the European Society of Cardiology. Eur Heart J 23 (2002) 1809-1840
10. Bassand J.P., Hamm C.W., Ardissino D., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J 28 (2007) 1598-1660
11. Avezum A., Makdisse M., Spencer F., et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 149 (2005) 67-73
12. Tran C.T., Laupacis A., Mamdani M.M., et al. Effect of age on the use of evidence-based therapies for acute myocardial infarction. Am Heart J 148 (2004) 834-841
13. Bertoni A.G., Bonds D.E., Lovato J., et al. Sex disparities in procedure use for acute myocardial infarction in the United States, 1995 to 2001. Am Heart J 147 (2004) 1054-1060
14. Peterson E.D., Pollack Jr. C.V., Roe M.T., et al. Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. J Am Coll Cardiol 42 (2003) 45-53
15. Budaj A., Brieger D., Steg P.G., et al. Global patterns of use of antithrombotic and antiplatelet therapy in patients with acute coronary events. Insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 146 (2003) 999-1006
16. Fox K.A., Goodman S.G., Anderson Jr. F.A., et al. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2003) 1414-1424
17. Mehta R.H., Montoye C.K., Gallogly M., et al. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. J Am Med Assoc 287 (2002) 1269-1276
18. Grol R., and Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet 362 (2003) 1225-1230
19. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
20. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
21. The Clopidogrel in Unstable angina to prevent Recurrent Events Trials Investigators (CURE). Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
22. Danchin N., Hanania G., Grenier O., et al. Trends in discharge prescriptions for patients hospitalized for acute coronary syndromes in France from 1995 to 2000. Data from the Usik 1995, Prevenir 1, Prevenir 2 and Usic 2000 surveys. Ann Cardiol Angeiol (Paris) 52 (2003) 1-6
23. Danchin N., Blanchard D., Steg P.G., et al. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation 110 (2004) 1909-1915
24. Danchin N., Grenier O., Ferrieres J., et al. Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. Heart 88 (2002) 159-162
25. Danchin N., Kadri Z., Cambou J.P., et al. Management of patients admitted for acute myocardial infarction in France from 1995 to 2000: time to admission dependent improvement in outcome. Arch Mal Coeur Vaiss 98 (2005) 1149-1154
26. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 357 (2001) 995-1001
27. Tunstall-Pedoe H., Vanuzzo D., Hobbs M., et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 355 (2000) 688-700
28. Mandelzweig L., Battler A., Boyko V., et al. The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J 27 (2006) 2285-2293
29. Fox K.A., Steg P.G., Eagle K.A., et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 297 (2007) 1892-1900
30. Granger C.B., Steg P.G., Peterson E., et al. Medication performance measures and mortality following acute coronary syndromes. Am J Med 118 (2005) 858-865
31. Blomkalns A.L., Chen A.Y., Hochman J.S., et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) national quality improvement initiative. J Am Coll Cardiol 45 (2005) 832-837
32. Bradshaw P.J., Jamrozik K., Gilfillan I., et al. Preventing recurrent events long term after coronary artery bypass graft: suboptimal use of medications in a population study. Am Heart J 147 (2004) 1047-1053
33. Tricoci P., Roe M.T., Mulgund J., et al. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med 166 (2006) 806-811
34. Devlin G.P., Anderson F.A.J., Heald S., et al. Management and outcomes of lower-risk patients presenting with acute coronary syndromes in a multinational observational registry. Heart (2005)
35. Fox K.A., Mehta S.R., Peters R., et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 110 (2004) 1202-1208
36. Weintraub W.S., Mahoney E.M., Lamy A., et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol 45 (2005) 838-845
37. Cambou J.P., Ferrières J., Gourdy P., et al. De PREVENIR-1 A PREVENIR-3: La prévention secondaire en France: quelles prescriptions après infarctus du myocarde? (From PREVENIR-1 to PREVENIR-3: secondary prevention in France: what prescriptions after myocardial infarction). Etud Eval Cardiovasc 7 (2000) 103-109
38. Ferrari E., Benhamou M., Cerboni P., et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 45 (2005) 456-459
39. Bhatt D.L., and Topol E.J. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 148 (2004) 263-268
40. Bhatt D.L., Fox K.A., Hacke W., et al. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 150 (2005) 401